T1	HMM 2325 2365	with a projected median overall survival
T2	HMM 2377 2384	months.
T3	HMM 2385 2410	Marrow and blood (T cell)
T4	HMM 2560 2603	had a median of 100% donor (T cell)-derived
T5	HMM 2609 2650	There has been no secondary graft failure
T6	HMM 2677 2702	patient died of pneumonia
T7	HMM 2708 2718	1 of liver
T8	HMM 2767 2847	Bu as pretransplant conditioning is safe in high-risk myeloid leukemia patients;
T9	HMM 2852 2897	clofarabine is sufficiently immunosuppressive
T10	HMM 3049 3083	evaluate the antileukemic efficacy
T11	HMM 3106 3107	.
T12	HMM 3108 3162	Bu as pretransplant conditioning therapy are warranted
